Affimed N.V.

-0.04 (-0.55%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)964.13M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$11.39 Million
Adjusted EPS-$0.14
See more estimates
10-Day MA$8.39
50-Day MA$9.35
200-Day MA$6.25
See more pivots

Affimed N.V. Stock, NASDAQ:AFMD

Technologiepark, Im Neuenheimer Feld 582, Heidelberg, Baden Wuerttemberg 69120
Phone: +49.6221.6743.60
Number of Employees: 163


Affimed NV engages in the discovery and development of cancer immunotherapies. It offers ROCK novel proprietary antibody platform, which delivers types of next-generation tetravalent antibody formats, including bispecific and trispecific innate cell engagers. It operates through the following geographical segments: Germany, Europe, and USA. The company was founded in 2000 and is headquartered in Heidelberg, Germany.